Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Murepavadin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | EPS15 | P42566 | 1/20 | 0.54 |
| ▸ | OXTR | P30559 | 4/20 | 0.53 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.51 |
| ▸ | CIB1 | Q99828 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.50 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577901 | 0.94 | EPS15 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30577898 | 0.94 | EPS15 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30577899 | 0.94 | EPS15 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30577900 | 0.94 | EPS15 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29411880 | 0.85 | EPS15 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30480651 | 0.83 | HDAC3 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29714778 | 0.80 | NECTIN4 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10795629 | 0.80 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11029594 | 0.80 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24358359 | 0.80 | CIB1 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| EP-4041275-B1 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | FARSIGHT MEDICAL TECH SHANGHAI CO LTD (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-3952929-B1 | REUSABLE URINARY CATHETER PRODUCTS | HOLLISTER INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260007854-A1 | REUSABLE URINARY CATHETER PRODUCTS | HOLLISTER INC (US) | 2026-01-08 | — | — | US | claimed |
| US-12440644-B2 | Reusable urinary catheter products | HOLLISTER INCORPORATED (US) | 2025-10-14 | — | — | US | claimed |
| WO-2025059553-A1 | CHIMERIC MOLECULES FOR COMPLEMENT IMMUNE RECRUITMENT | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025017206-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2025-01-23 | — | — | WO | claimed |
| US-20240100121-A1 | COMPOSITIONS OF A BETA-HAIRPIN PEPTIDOMIMETIC AND AEROSOL DOSAGE FORMS THEREOF | SPEXIS AG (CH) | 2024-03-28 | — | — | US | claimed |
| CN-116870135-A | Treatment and prevention of kidney toxin induced kidney injury | 睿诺医疗科技（上海）有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20230173017-A1 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | FARSIGHT MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD. (CN) | 2023-06-08 | — | — | US | claimed |
| EP-4041275-A1 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | Farsight Medical Technology (Shanghai) Co., Ltd. (CN) | 2022-08-17 | — | — | EP | claimed |
| US-20220226605-A1 | REUSABLE URINARY CATHETER PRODUCTS | HOLLISTER INCORPORATED | 2022-07-21 | — | — | US | claimed |
| US-20220184173-A1 | STABLE PHARMACEUTICAL FORMULATIONS OF PEPTIDE AND PROTEIN DRUGS | EMPHASCIENCE INC (US) | 2022-06-16 | — | — | US | claimed |
| EP-3952929-A1 | REUSABLE URINARY CATHETER PRODUCTS | Hollister Incorporated (US) | 2022-02-16 | — | — | EP | claimed |
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106958-A1 | SOFT MIST INHALER AND IMPROVEMENTS THEREFOR | Transpire Bio Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4041275-B1 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | FARSIGHT MEDICAL TECH SHANGHAI CO LTD (CN) | 2026-05-20 | — | — | EP | disclosed |
| WO-2022076505-A1 | GELMA POLYMER COMPOSITIONS AND USES THEREOF | GELMEDIX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114341156-A | Ferritin encapsulated with peptides | 味之素株式会社 | 2022-04-12 | — | — | CN | disclosed |
| EP-3952929-A1 | REUSABLE URINARY CATHETER PRODUCTS | Hollister Incorporated (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173017-A1 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | ATP6V1B1, REN, GLS | HDAC3 2568/4885HDAC4 2766/4885HDAC1 2459/4885 |
| US-20260007854-A1 | REUSABLE URINARY CATHETER PRODUCTS | AQP3, AQP1, SLC14A1 | HDAC3 2908/4885HDAC4 3387/4885HDAC1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.